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Abstract
The pathogenetic role of vascular endothelial growth factor (VEGF) in long-term retinal and kidney complications of
diabetes has been demonstrated. Conversely, little is known in diabetic neuropathy. We examined the modulation of VEGF
pathway at mRNA and protein level on dorsal root ganglion (DRG) neurons and Schwann cells (SC) induced by
hyperglycaemia. Moreover, we studied the effects of VEGF neutralization on hyperglycemic DRG neurons and
streptozotocin-induced diabetic neuropathy. Our findings demonstrated that DRG neurons were not affected by the
direct exposition to hyperglycaemia, whereas showed an impairment of neurite outgrowth ability when exposed to the
medium of SC cultured in hyperglycaemia. This was mediated by an altered regulation of VEGF and FLT-1 receptors.
Hyperglycaemia increased VEGF and FLT-1 mRNA without changing their intracellular protein levels in DRG neurons,
decreased intracellular and secreted protein levels without changing mRNA level in SC, while reduced the expression of the
soluble receptor sFLT-1 both in DRG neurons and SC. Bevacizumab, a molecule that inhibits VEGF activity preventing the
interaction with its receptors, restored neurite outgrowth and normalized FLT-1 mRNA and protein levels in co-cultures. In
diabetic rats, it both prevented and restored nerve conduction velocity and nociceptive thresholds. We demonstrated that
hyperglycaemia early affected neurite outgrowth through the impairment of SC-derived VEGF/FLT-1 signaling and that the
neutralization of SC-secreted VEGF was protective both in vitro and in vivo models of diabetic neuropathy.
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Introduction
Neuropathy is a chronic complication of both type 1 and type 2
diabetes that severely affects patients’ quality of life and increases
morbidity and mortality [1]. Once established, diabetic axonal
damage fails to recover due to a number of events, including the
loss of innervated targets and the chronic denervation of Schwann
cells (SC) [2]. Different mechanisms have been claimed as critical
in the pathogenesis of diabetic neuropathy (DN), including
abnormal metabolic and neurovascular pathways, growth factor
deficiency, and extracellular matrix remodeling [3]. Nevertheless,
hyperglycaemia remains the most important trigger for the
development of DN and its control is crucial for the course of
the disease [3,4]. The complex relationship between axons and SC
in nerve degeneration and regeneration [5] likely plays a critical
role also in DN. Previous studies showed that hyperglycaemia can
directly affect SC inducing in vitro apoptosis [6], altering the
secretion of growth factors [7,8] and interfering with proliferation
and migration abilities [9], thus suggesting an effect on this cell
type. However, little is known on how hyperglycaemia interferes
with the supporting role of SC on axonal growth in cultured dorsal
root ganglion (DRG) neurons.
Here we describe that SC mediate the impairment of neurite
outgrowth caused by hyperglycaemia through increased secretion
of vascular endothelial growth factor (VEGF) and altered fms-
related tyrosine kinase 1 (FLT-1) receptor signaling, and that
bevacizumab, a molecule that inhibits VEGF activity preventing
the interaction to its receptors, in vitro prevented axonal
outgrowth failure, and in vivo both rescued and restored in a
dose-dependent fashion DN in rats.
Materials and Methods
Animal Experimentation
The Statement of Compliance (Assurance) with Standards for
Humane Care and Use of Laboratory Animals has been reviewed
(10/28/2008) and approved by the National Institutes of Health-
Office for Protection from Research Risks (5023-01, expiration
10/31/2013). The IRCCS Foundation ‘‘Carlo Besta’’ Neurolog-
ical Institute adheres to the principles set out in the following laws,
regulations, and policies governing the care and use of laboratory
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e108403
animals: Italian Legislative Decree 116 of Jan. 27, 1992
Authorization 169/94-A issued Dec. 19, 1994 by Ministry of
Health; IRCCS Foundation ‘‘Carlo Besta’’ Institutional Regula-
tions and Policies providing internal authorization for persons
conducting animal experiments; the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, 1996); and European Union
directives and guidelines (Legislative Decree 626, September 19,
1994; 89/391/CEE, 89/654/CEE, 89/655/CEE, 89/656/CEE,
90/269/CEE, 90/270/CEE, 90/394/CEE, 90/679/CEE).
Cell culture
Primary DRG culture were freshly isolated from embryonic age
day-15 Sprague-Dawley rats. Dissected embryonic DRG were
enzymatically dissociated with 0.25% trypsin in L-15 medium as
previously described [10]. Cells were plated in 24-well plates on
collagen-coated glass coverslips, pretreated with poly-D-lysine
(Sigma-Aldrich, St. Louis, MO). These cultures contain mainly
sensory neurons and SC. DRG neuron monocultures were
obtained after exposition to ARA-C (10 mM) for 72 hours [11]
and maintained in Neurobasal medium (Gibco Invitrogen, Grand
Island, NY) containing 25 mM glucose, supplemented with 1xB27
without antioxidants, penicillin (1 U/L), streptomycin (1 U/L),
and nerve growth factor (10 ng/ml). All experiments with DRG
culture were performed 7 day after initial plating. SC monocul-
tures were obtained from 2 day-old rat sciatic nerves, purified
using a modified Brockes’ method [12], and maintained in
DMEM 10% FBS, neuregulin (20 ng/ml) and forskolin (2 mM).
Twenty-four hours before the experiments, medium was changed
to neuronal medium. Hyperglycemic condition was obtained
(where not otherwise specified) adding 20 mM glucose to achieve a
final concentration of 45 mM [13,14]. DRG neuron monocultures
were exposed to SC-conditioned medium collected from control
and hyperglycemic (45 mM for 24 hours) cultures. Co-cultures
and monocultures were exposed to cisplatin or paclitaxel (10 mg/
ml and 250 ng/ml for 24 hours, respectively; Sigma-Aldrich,
St.Louis, MO) as positive control [15,16]. Hyperglycemic and
control cultures were exposed to bevacizumab (Avastin; Genen-
tech Inc., Roche Group, San Francisco USA), 0.1 and 0.25 mg/
ml for 24 hours to evaluate the protective effect [17].
Assessment of neuronal apoptosis
Cells were fixed and stained with in situ DNA nick labeling
(DeadEnd Fluorometric TUNEL System, Promega, Madison,
WI), co-stained with DAPI and anti-BIII tubulin antibody (TuJ1,
Berkley Antibody Company, Richmond, CA) and anti-glial
fibrillary acidic protein (GFAP, Dako, Glostrup, Denmark)
antibodies for neuron and SC identification, respectively. Apo-
ptotic cells were counted using a fluorescence microscope.
Apoptosis was also assessed by flow-cytometry using Annexin V/
PI assay (Immunostep, Salamanca, Spain) and processed accord-
ing to manufacturer’s instructions. Early and late apoptosis were
evaluated on fluorescence 2 (for propidium iodide) versus
fluorescence 1 (for annexin) plots. The percentage of cells stained
by annexin V alone was recorded as early apoptosis, whereas the
percentage of cells stained by both annexin V and propidium
iodide was recorded as late apoptosis.
Assessment of mitochondrial membrane potential
changes
Mitochondrial membrane potential was measured using the J-
aggregate forming lipophilic cation (JC-1; Molecular Probes,
Eugene, OR) [18,19]. Dissociated DRG cells were exposed to
hyperglycaemia, cisplatin or paclitaxel. After 24 hours, cells were
washed and incubated with JC-1 (2.5 mg/ml) for 30 min according
to manufacturer’s protocol. The fluorescence emission pattern was
analyzed by flow-cytometry using two dimensional green versus
red fluorescence plots. The red-to-green ratio allows comparative
measurements of membrane potential between cell populations.
Assessment of axonal outgrowth
After 24 hours exposure to treatments, cells were fixed in 4%
paraformaldehyde and stained with fluorescent anti-TuJ1 anti-
body. Neurite outgrowth was assessed measuring the longest
neurite on each of at least 100 randomly selected neurons per
condition, using an image analysis system on fluorescence
microscope (Image Pro-Plus, Media Cybernetics, Silver Spring,
MD) [20–22]. Each condition was assessed in duplicate for at least
three times using cultures prepared on separate days.
Rat cytokine array
Cytokine profile expression in SC-conditioned medium was
evaluated by Proteome Profiler Rat Cytokine Array Kit, Panel A
(R&D Systems, Minneapolis, MN) which detects 29 growth
factors, cytokines, and chemokines (CXCL1/CINC-1, IL-1ra, L-
Selectin, CXCL3/CINC-2 alpha/beta, IL-2, CXCL9/MIG,
CINC-3, IL-3, CCL3/MIP-1 alpha, CNTF, IL-4, CCL20/MIP-
3 alpha, Fractalkine/CXC3CL1, IL-6, CCL5/RANTES, GM-
CSF, IL-10, CXCL7/Thymus Chemokine, ICAM-1, IL-13,
TIMP-1, IFN-gamma, IL-17, TNF-alpha, IL-1 alpha,
CXCL10/IP-10, VEGF, IL-1 beta, LIX). Expression was
analyzed following manufacturer’s recommendations. The signals
were visualized using an ECL system (Amersham Pharmacia
Biotech, Piscataway, NJ, USA). Spot densities were measured and
compared using Image-J software.
ELISA assay of secreted VEGF and sFLt-1 protein
Enzyme-linked immunosorbent assay (ELISA) were performed
with commercial ELISA kit for VEGF (R&D Systems, Minnea-
polis, MN) and sFLT-1 (Novatein Biosciences, Cambridge, MA).
Conditioned medium was collected from wells 24 hours after
treatment. Assays were performed in duplicate and values were
compared with standards provided by the kits.
Real-time PCR assay
Total RNA was isolated 24 hours after treatment with VEGF,
glucose and/or bevacizumab from cultured DRG cells or SC using
Trizol (Invitrogen, San Giuliano Milanese, Italy) according to
manufacturer’s instructions. Precipitated RNA was dissolved in
RNase-free water and quantified; aliquots were prepared for
further analysis. RNA was analyzed using TaqMan qRT-PCR
(quantitative real-time PCR) instrument (CFX384 real time
system, Bio-Rad Laboratories, Segrate, Italy) by iScriptTM
onestepRT-PCR kit for probes (Bio-Rad Laboratories, Segrate,
Italy). Specific TaqMan probes (Life Techonologies, Monza, Italy)
were VEGFa (Rn01511601_m1) and VEGFR-1 (Flt1)
(Rn00570815_m1). Samples were run in 98 wells in triplicate as
multiplexed reactions with a normalizing internal control (18s).
Data were confirmed by assay of two additional house-keeping
genes: actin (Rn00667869_m1) and cyclophilin A
(Rn00690933_m1). Comparative cycle threshold method was
used to calculate the relative target gene expression. Each
condition was assessed in duplicate for at least three times.
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Western blot
Total proteins from treated cell cultures were extracted using
Trizol according to manufacturer’s protocol. Protein quantifica-
tion was performed by standard Bicinchoninic acid (BCA, Pierce,
Rockford, USA) method; 30 mg of protein per lane were applied,
separated by electrophoresis on 10% polyacrylamide gels and
transferred onto methanol treated PVDF membranes. Membranes
were saturated with 5% fat-free dried milk in Tween-triphosphate
buffer solution and incubated overnight at 4uC with primary
antibodies (anti-VEGF antibody, rabbit policlonal, Abcam, 1:600;
anti-VEGF Receptor 1 antibody, rabbit polyclonal, Abcam 1:200;
anti-alpha tubulin, mouse monoclonal, 1:800) diluted in the same
buffer, washed and exposed to peroxidise conjugated secondary
antibodies (donkey anti-rabbit or anti-mouse IgG 1:10000, GE
Healthcare Europe, Milan, Italy). Specific signals were revealed
with the chemiluminescence detection kit (ECL, GE Healthcare
Europe, Milan, Italy). Semiquantitative densitometric analysis was
performed by scanning the bands with image-analysis software
(Image-J). Results were normalized for TuJ1.
Nociceptive thresholds
Thermal nociceptive threshold to radiant heat was quantified
measuring withdrawal latency on hot plate [23], defined as the
time laps between placement and hindpaw withdrawal and licking.
Each animal was tested twice separated by a 30-minute rest
interval. Mechanical nociceptive threshold was quantified by the
Randall–Selitto paw withdrawal test [23] using an analgesy meter
(Ugo Basile, Comerio, Italy) that generates a linearly increasing
mechanical force. Result represents the maximal pressure (grams)
tolerated by the animal. Rats were accustomed to the devices 3
days before performing the tests. At each time point, animals
underwent three trials and values were averaged.
Electrophysiological techniques
Antidromic sensory tail-nerve conduction velocity (NCV) was
assessed by Myto EBNeuro electromyograph (EBNeuro, Firenze,
Italy). The latency of potential was recorded in the two sites after
nerve stimulation (stimulus duration, 100 msec; filter, 1 Hz to
5 MHz) was determined (peak to peak), and NCV calculated
accordingly. Data were collected with a MP100 acquisition system
(Biopac Systems, Santa Barbara, CA). All recordings were
performed under standard conditions at controlled temperature
(room and animals). Core temperature was maintained at 37uC by
using heating pads and lamps.
In vivo experimental design
Figure 1 shows the experimental flow-charts. Diabetes was
induced in overnight fasted male Sprague Dawley rats weighing
200–220 g (Charles River, Calco, Italy) by single intraperitoneal
(i.p.) injection of streptozotocin (STZ, Sigma-Aldrich, St. Louis,
MO), 60 mg/kg body weight, in sodium citrate buffer, pH 4.5.
Only diabetic rats with urine glucose.15 mM two days after STZ
injection were used. Rats were divided into four groups (n = 8) in
both the prevention and therapeutic schedules (controls, STZ,
STZ+bevacizumab 10 mg/kg, STZ+bevacizumab 20 mg/kg).
Control animals were weight, matched and given sodium citrate
buffer without STZ. Prevention protocol: diabetic rats were
randomized to receive i.p. bevacizumab at either 10 or 20 mg/
kg body weight at week 1 soon after diabetic induction, and at
week 4. NCV and nociceptive thresholds were measured at week 8
(4 weeks after last bevacizumab treatment). Therapeutic protocol:
diabetic rats underwent NCV and nociceptive threshold assess-
ment at week 7. Therefore, they were randomized to receive
bevacizumab at either 10 or 20 mg/kg body weight at week 8 and
12. NCV and nociceptive thresholds were measured at week 16 (4
weeks after last bevacizumab treatment). Body weight was
measured weekly in both groups.
Figure 1. Flow-chart of prevention and therapeutic protocols in streptozotocin-induced diabetic neuropathy. Diabetes was induced
by intraperitoneal (i.p.) injection of 60 mg/kg streptozotocin (STZ). Bevacizumab (10 or 20 mg/kg) was administered i.p. at the indicated times. Four
groups of Sprague Dawley rats (8 per group) were used in both the protocols (untreated, STZ untreated, STZ+bevacizumab 10 mg/kg, STZ+
bevacizumab 20 mg/kg). In the prevention protocol, bevacizumab was administered at week 1 (after confirmation of diabetes), and week 4; rats were
sacrificed at week 8. In the therapeutic protocol, bevacizumab was administered at week 8 and 12, and rats were sacrificed at week 16. Nerve
conduction velocity (NCV) and nociceptive threshold assessment were measured at the indicated times.
doi:10.1371/journal.pone.0108403.g001
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Statistic analysis
Data are presented as mean6standard deviation (SD). Differ-
ences were analyzed by Student’s unpaired t test or 1-way
ANOVA. P,0.05 was considered statistically significant.
Results
Hyperglycaemia did not increase DRG neuron or SC
apoptosis
Hyperglycaemia did not significantly affect DRG neuron
survival both in coculture (apoptotic cells/cells; ctrl
0.01460.004, glucose 45 mM 0.02460.005, glucose 90 mM
0.01660.003, glucose 135 mM 0.01260.003, glucose 180 mM
0.01460.002; Fig. 2A, B) and in monoculture (apoptotic cells/
cells: ctrl 0.03960.007, glucose 45 mM 0.06060.01, glucose
90 mM 0.03960.005, glucose 135 mM 0.0460.006, glucose
180 mM 0.0460.006, Fig. 2C) at any of the concentration
tested, whereas it increased SC apoptosis only at the highest
concentrations both in coculture (apoptotic cells/cells: ctrl
0.01560.002, glucose 45 mM 0.02460.004, glucose 90 mM
0.02360.004, glucose 135 mM 0.02360.004 p,0.05 vs ctrl,
glucose 180 mM 0.03160.004 p,0.0001 vs ctrl, Fig. 2B) and in
monoculture (apoptotic cells/cells: ctrl 0.01060.002, glucose
45 mM 0.01660.006, glucose 90 mM 0.01260.004, glucose
135 mM 0.00660.004, glucose 180 mM 0.03160.013 p,0.005
vs ctrl, Fig. 2D). Conversely, both neurons and SC showed high
rate of apoptosis after exposure to cisplatin and paclitaxel
demonstrating that absence of intrinsic resistance (apoptotic
Figure 2. Hyperglycaemia did not increase DRG neuron or Schwann cell (SC) apoptosis. (A) Neuron-SC co-cultures showed a modest
increase of apoptosis rate only at the highest glucose concentration; paclitaxel (tax) and cisplatin (cis) exposition was used as positive controls. (B) In
DRG neuron monocultures, hyperglycaemia did not induce apoptosis. (C) Tubulin-III and GFAP staining demonstrated that apoptosis mainly involved
SC. (D) SC monocultures showed a mild increase of apoptosis rate at the highest glucose concentrations, similar to that observed in co-cultures (see
C). (E) Flow cytometry by annexin V/PI assay confirmed the absence of apoptosis in co-cultures exposed to hyperglycaemia. (F) Representative
cytogram showing the absence of apoptosis in control co-culture (ctrl) and after 24 hour exposition to hyperglycaemia 45 mM (hg), compared to the
high apoptosis rate after exposition to anti-neoplastic compounds (tax, cis). Data are expressed as mean6SEM of independent experiments (n= 8)
*p,0.05; **p,0.005; ***p,0.0005 vs controls; #p,0.05; ##p,0.005; ###p,0.0005 vs SC controls.
doi:10.1371/journal.pone.0108403.g002
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cells/cells DRG neuron in monoculture ctrl 0.03960.007,
paclitaxel 250 ng/ml 0.04960.014, cisplatin 10 ug/ml
0.05560.014; apoptotic cells/cells DRG neuron in coculture ctrl
0.01460.004, paclitaxel 250 ng/ml 0.06160.014 p,0.0001 vs
ctrl, cisplatin 10 ug/ml 0.0660.033 p,0.0001 vs ctrl; apoptotic
cells/cells SC in monoculture ctrl 0.01060.002, paclitaxel
250 ng/ml 0.0260.003 p,0.005 vs ctrl, cisplatin 10 ug/ml
0.14560.02 p,0.0001 vs ctrl; apoptotic cells/cells SC in coculture
ctrl 0.01560.002, paclitaxel 250 ng/ml 0.10160.015 p,0.0001
vs ctrl, cisplatin 10 ug/ml 0.28460.014 p,0.0001 vs ctrl;
Fig. 2A–D). Flow-cytometry with annexin V/PI confirmed the
above described results both for early and late apoptosis (%
apoptosis: ctrl 6.361.3, glucose 45 mM 8.661.5, glucose 90 mM
8.863.5, glucose 135 mM 7.062.2, glucose 180 mM 6.361.3 p,
0.005 vs ctrl, paclitaxel 250 ng/ml 25.169.2 p,0.005 vs ctrl,
cisplatin 10 ug/ml 45.964.4 p,0.0001 vs ctrl; Fig. 2E–F).
Hyperglycaemia did not cause early loss of mitochondrial
membrane potential differential
Mitochondrial potential was assessed in DRG-co-cultures 24
hours after glucose (45 mM) or toxic compound exposure
(paclitaxel 250 ng/ml or cisplatin 10 ug/ml). Cisplatin exposure
caused an intense decrease of red/green fluorescence ratio (% of
cells in the lower-right quadrant 57.40612.82 vs ctrl 10.6563.95,
p,0.05) thus revealing mitochondrial depolarization. Conversely,
high glucose treated cultures did not show any significant change
in fluorescence plot (% of cells in the lower-right quadrant
10.8260.77 vs ctrl 10.6563.95, p.0.05). These findings indicated
that hyperglycaemia did not affect mitochondrial membrane
potential in our experimental condition (Fig. 3A, B).
Hyperglycaemia-conditioned SC medium impaired
neurite outgrowth and showed high VEGF level
In DRG co-cultures, 24-hour exposure to increasing hypergly-
caemia caused a significant decrease of neurite outgrowth length
(axonal length % difference; ctrl 100, glucose 45 mM 85.566.2
p,0.05 vs ctrl, glucose 90 mM 89.464.0 p,0.05, glucose
135 mM 73.964.6 p,0.005 vs ctrl, glucose 180 mM 71.961.8
p,0.0001 vs ctrl, paclitaxel 250 ng/ml 63.9611.6 p,0.05 vs ctrl,
cisplatin 10 ug/ml 70.565.2 p,0.005 vs ctrl; Fig. 4A). Con-
versely, in DRG neuron monocultures hyperglycaemia did not
affect neurite length, suggesting that SC could mediate the
neuronal toxicity. This SC-mediated effect appeared hyperglycae-
mia-specific, because exposure of DRG neuron monocultures to
cisplatin caused neurite outgrowth decrease (axonal length %
difference: ctrl 100, glucose 45 mM 96.365.1, glucose 90 mM
97.364.8, glucose 135 mM 106.2611.7, glucose 180 mM
95.264, 9, paclitaxel 250 ng/ml 116.9617.7, cisplatin 10 ug/ml
65.3611.2 p,0.05 vs ctrl; Fig. 4B). When DRG neuron
monocultures were exposed to the medium of SC cultured in
hyperglycaemia, neurite outgrowth decreased (axonal length %
difference 81.1361.2 p,0.0001 vs ctrl 100) by similar extent to
that observed in DRG co-cultures exposed to hyperglycaemia
(axonal length % difference, ctrl 100; glucose 45 mM 109.3610.4;
Fig. 4C). These findings suggested that SC secreted a molecule
able to exert a toxic effect on DRG neurons. To investigate this
hypothesis, we performed a cytokine profile array in the medium
of SC monoculture exposed and not exposed to hyperglycaemia.
We found higher level of VEGF in the medium of SC
monoculture exposed to hyperglycaemia than in control medium
(pixel density intensity; ctrl 0.69260.005; hg 45 mM 0.94760.050
p,0.05; Fig. 4D and E). No difference was found in the levels of
all the others cytokines and chemokines analyzed (see Method
section for the list of cytokines and chemokines analyzed). This
suggested that DRG neurons neurite length decrease may depend
on increased level of SC-derived VEGF.
Hyperglycaemia induced post-translational VEGF
regulation in SC
We performed ELISA assay for VEGF level in the medium of
DRG neuron and SC. Basal VEGF concentration was 1464 pg/
ml in DRG neuron monoculture medium, 3-fold lower than in SC
(4269 pg/ml) and co-culture medium (4866 pg/ml). After 24
hour exposure to 45 mM glucose, VEGF concentration signifi-
cantly increased in SC monoculture (45 mM glucose 5469 pg/ml
vs ctrl 4269 pg/ml, p,0.05) and DRG co-culture (45 mM
glucose 5665 pg/ml vs ctrl 4866 pg/ml, p,0.05) medium,
whereas it did not significantly change in DRG neuron
monoculture medium (45 mM glucose 1364 pg/ml vs ctrl
1464 pg/ml; Fig. 5A). We next performed VEGF mRNA
Figure 3. Hyperglycaemia did not affect mitochondrial mem-
brane potential. (A) JC-1 fluorescence emission measurements
showed a reduction in red-to-green ratio in neurons exposed to
cisplatin (cis) but not to hyperglycaemia (45 mM) nor paclitaxel (tax)
(n=4), *p,0.05 vs ctrl. (B) Representative flow cytogram of mitochon-
drial membrane potential in co-cultures using JC-1. The shift of JC-1
fluorescence from red (FL2) to green (FL1) indicates a collapse of
mitochondrial membrane potential.
doi:10.1371/journal.pone.0108403.g003
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quantification by real-time PCR and VEGF protein quantification
by Western blot. After 24 hour exposure to 45 mM glucose,
VEGF mRNA expression did not significantly change in SC
(relative mRNA expression 144631 vs ctrl 100), whereas
intracellular VEGF protein level decreased (relative protein
expression 88.4613.8 p,0.05 vs ctrl 100). According to the
ELISA assay, DRG neuron monocultures in basal condition
expressed very low VEGF mRNA level compared to SC
(0.00460.001 vs 0.02060.01; p,0.01). VEGF mRNA level was
significantly increased in DRG neuron monocultures by 24 hour
exposure to 45 mM glucose (relative mRNA expression normal-
ized to 18s: 194637 vs ctrl 100; relative mRNA expression
normalized to actin 188624 vs ctrl 100; relative mRNA
expression normalized to cyclophilin A 172629 vs ctrl 100, p,
0.05), whereas intracellular protein level did not change (relative
protein expression 11363 vs ctrl 100) (Fig. 5B–D). To test the
hypothesis that VEGF decreased neurite outgrowth, DRG
neurons were treated for 24 hours with VEGF in a wide range
concentration (from 10 pg/ml to 100 ng/ml). VEGF significantly
decreased the neurite outgrowth (axonal length mm ctrl 93.862.7;
VEGF 10 pg/ml 94.565.2; VEGF 100 pg/ml 81.765.2 p,0.05
vs ctrl; VEGF 1000 pg/ml 83.964.2 p,0.05 vs ctrl; VEGF
10 ng/ml 83.364.7 p,0.05 vs ctrl; VEGF 50 ng/ml 81.663.1
p,0.05 vs ctrl; VEGF 100 ng/ml 72.964.7 p,0.05 vs ctrl;
Fig. 5E), suggesting that VEGF had a key role in the decrease of
neurite length found in DRG co-cultures exposed to hyperglycae-
mia.
Bevacizumab prevented hyperglycaemia-mediated
neurite outgrowth impairment and normalized FLT-1
In DRG co-cultures exposed to hyperglycaemia, bevacizumab
(0.1 and 0.25 mg/ml) normalized neurite outgrowth length
without affecting control cell cultures (axonal length %difference:
ctrl 100; bev 0.25 mg/ml 100.461.3; hg 8062.4 p,0.0001 vs ctrl;
hg+bev 0.1 mg/ml 95.266.3 p,0.05 vs hg; hg+bev 0.25 mg/ml
98.563.3 p,0.005 vs hg; Fig. 6A). RT-PCR showed that FLT-1
mRNA was constitutively expressed in DRG neurons and SC at
low level (0.002060.0013 and 0.001560.0017, respectively).
Hyperglycaemia significantly upregulated FLT-1 mRNA in
DRG neuron monocultures (relative expression normalized to
18s 165623 vs ctrl 100; relative expression normalized to actin
24460.5 vs ctrl 100; relative expression normalized to cyclophilin
A 22365.1 vs ctrl 100; p,0.05), whereas it did not change its level
in DRG co-cultures (131632 vs ctrl 100) and SC monocultures
(121641 vs ctrl 100). At the same time, hyperglycaemia
significantly decreased FLT-1 protein level in SC monocultures
(relative protein expression 61611 vs ctrl 100), whereas FLT-1
protein level remained unchanged in neuron monocultures
(55628 vs ctrl 100) and DRG co-cultures (168692 vs ctrl 100).
Soluble FLT-1 (sFLT-1) protein level decreased after 24 hours
exposure to 45 mM glucose both in SC (relative sFLT1 protein
expression 64.49612.0 p,0.05 vs ctrl 100), neuron monoculture
(53.367.8 p,0.05 vs ctrl 100; mean6SE), and DRG co-culture
medium (62.768.9 p,0.05 vs ctrl 100; Fig. 6B–F). Bevacizumab
prevented FLT-1 mRNA upregulation induced by hyperglycaemia
in DRG neuron monocultures (relative expression normalized to
18s 103613 vs hg 165623; relative expression normalized to
Figure 4. Hyperglycaemia significantly and in a dose-dependent fashion affected neurite outgrowth. (A) Exposure to increasing glucose
concentrations induced a significant dose-dependent decrease of neurite outgrowth in neuron-SC co-cultures (B) but not in neuron monocultures.
(C) Exposure of neuron monocultures to hyperglycaemia-conditioned SC monoculture medium caused a significant decrease of the neurite
outgrowth. All data are normalized to control and presented as mean6SEM of independent experiments (n= 8) *p,0.05; **p,0.005; ***p,0.0005 vs
control. (D) Cytokine array of hyperglycaemia-conditioned SC monoculture medium showing increase of VEGF compared to control. (E) Data are
expressed as relative levels of VEGF.
doi:10.1371/journal.pone.0108403.g004
VEGF Block Counteracts Diabetic Neuropathy
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e108403
cyclophilin A 165639 vs hg 22365; p,0.05) and increased FLT-1
protein in SC monocultures (183.6641.8 p,0.05 vs hg 61611).
sFLT-1 level remained unchanged in DRG co-cultures (61.663.9
vs hg 64.49612.0; Fig. 6B–F).
Bevacizumab improved nerve functions in STZ-diabetic
neuropathy rats
Bevacizumab did not have significant effects on weight and non-
fasted plasma glucose in diabetic rats at both the concentrations
administered. In the preventive protocol, bevacizumab prevented
the increase of hindpaw thermal nociceptive latency (seconds ctrl
21.462.6; STZ 35.863.3 p,0.01 vs ctrl; STZ+bev.10 mg/kg
30.562.2; STZ+bev.20 mg/kg 27.463.4 p,0.05 vs STZ;
Fig. 7A), the decrease of mechanical thresholds (grams ctrl
164.2621.3; STZ 94.6610 p,0.05 vs ctrl; STZ+bev.10 mg/kg
103.8610.2; STZ+bev.20 mg/kg 162.2616.2 p,0.05 vs STZ;
Fig. 7B), and the impairment of NCV in a dose-dependent
fashion (m/s ctrl 29.460.8; STZ 20.260.8 p,0.01 vs ctrl; STZ+
bev.10 mg/kg 27.361.9 p,0.05 vs STZ; STZ+bev.20 mg/kg
30.061.9 p,0.001 vs STZ; Fig. 7C) in diabetic rats. In the
therapeutic protocol, bevacizumab normalized thermal response
latency (seconds ctrl 18.062.0; STZ 37.562.9 p,0.05 vs ctrl;
Figure 5. Hyperglycaemia-induced post-translational regulation of VEGF. (A) Exposure to glucose 45 mM for 24 hours increased the level
of secreted VEGF in neuron-SC co-cultures and SC monocultures. Data are express as percentage difference between their own control in
independent experiments (n=5) *p,0.05. (B) Hyperglycaemia significantly increased VEGF mRNA only in neuron monocultures (n=5). (C)
Representative and (D) quantitative western blot (WB) demonstrating VEGF decrease in hyperglycaemia-conditioned SC monocultures compared
with control SC monocultures. VEGF level was not affected in neuron monocultures. Data are expressed as mean6SEM of independent experiments
(n=4) *p,0.05 vs controls. (E) VEGF induced a significant reduction in axonal outgrowth in neuron/Schwann cells coculture. Data are expressed as
mean6SEM of independent experiments (n= 3) *p,0.05 vs controls.
doi:10.1371/journal.pone.0108403.g005
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STZ+bev.10 mg/kg 20.863.4 p,0.05 vs STZ; STZ+bev.20 mg/
kg 23.463 p,0.05 vs STZ; Fig. 7D), restored mechanical
thresholds (grams ctrl 175.4610.2; STZ 73.663.6 p,0.001 vs
ctrl; STZ+bev.10 mg/kg 114.7618.1; STZ+bev.20 mg/kg
107.2619.7 p,0.05 vs ctrl; Fig. 7E), and rescued NCV (m/s
ctrl 34.161.7; STZ 24.661.1 p,0.001 vs ctrl; STZ+bev.10 mg/
kg 29.461.8 p,0.05 vs STZ; STZ+bev.20 mg/kg 29.562.1 p,
0.01 vs STZ; Fig. 7F) in diabetic rats.
Discussion
In patients, DN typically presents as a dying-back axonopathy,
suggesting that hyperglycaemia targets axons rather than DRG
neurons [3] which primary impairment would lead to distinct non-
length-dependent clinical and neurophysiological abnormalities
[24]. DRG neurons are particularly vulnerable to toxic circulating
agents being supplied by fenestrated capillaries instead of the tight
blood-brain-barrier [25,26]. Furthermore, they have long axons
rich in mitochondria and are particularly susceptible to any
interference in energy metabolism, oxidative stress, and axonal
transport [27]. SC are involved in endogenous neuroprotective
pathways [28] and the reciprocal interaction with axons is
mandatory for the normal functions of nerves. Previous works
showed that hyperglycaemia can impair the secretion of SC-
Figure 6. Bevacizumab prevented hyperglycaemia-mediated neurite outgrowth impairment and normalized FLT-1. (A) bevacizumab
prevented the decrease of hyperglycaemia-mediated neurite outgrowth in neuron-SC co-cultures (n=5) and (B) the increase of FLT-1 mRNA in
neurons monocultures (n= 5). (C) Representative and (D) quantitative western blot (WB) (n=5) showing the significant decrease of FLT-1 in
hyperglycaemia-conditioned SC monocultures and the preventive effect of bevacizumab. (E) sFLT-1 decreased in the medium of all neuron and SC
monocultures and co-cultures exposed to hyperglycaemia (n= 5). (F) Bevacizumab did not affect sFLT-1 level in hyperglycaemia-conditioned co-
cultures (n= 3). Data are expressed as mean6SEM of independent experiments. *p,0.05 vs controls; #p,0.05 vs hyperglycaemia; ##p,0.01 vs
hyperglycaemia.
doi:10.1371/journal.pone.0108403.g006
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derived cytokines and growth factors, and affect axonal growth
[8].
We used an in vitro experimental approach using co-cultures
and monocultures of DRG neurons and SC to investigate the
effects of hyperglycaemia on each cell type and their relationship.
The use of embryos allows a high content of cells with a higher
efficiency in isolating neurons in comparison to post-natal animals
and they have been shown to be an adequate and predictive model
for studying neuropathies [29]. Even if embryonic sensory neurons
have phenotypic differences from adult sensory neurons needing
an higher basal concentration of glucose (25 mM) than adult
neurons for survival and being dependent on neurotrophic factors
[30] for the first week in culture, it has been demonstrated that
aged embryonic DRG neurons cultured exhibit properties similar
to adult DRG neurons [31]. The equivalent of a 1.8-fold glucose
level above control value used was similar to the 1.5-fold increase
commonly found in diabetic patients [32]. In this setting,
confirming previous works [25], we found that hyperglycaemia
affected the ability of neurite outgrowth, whereas it did not induce
early or late DRG neuron apoptosis. Although neurite outgrowth
is a model of axon elongation rather than degeneration, our
findings support what has been clearly established in animal
models and patients with DN [3] and points to axons as the
primary target of hyperglycaemia-induced toxicity.
Our study demonstrated the pathogenetic role of SC-derived
VEGF/FLT-1 signaling, whose normalization after bevacizumab
treatment was protective in the in vitro model. We showed that
the exposition of DRG neurons monoculture to hyperglycaemia
did not affect neurite outgrowth, which did not differ from control
monocultures. Conversely, neurite outgrowth significant decreased
when DRG neuron monocultures were exposed to the medium of
SC cultured in hyperglycaemia. This effect was mediated by the
marked increase of VEGF in the medium of hyperglycaemia-
conditioned SC monoculture, as confirmed by the dose-dependent
impairment of neurite outgrowth after exposition of DRG co-
culture to VEGF. Previous studies showed that hyperglycaemia
directly stimulates the secretion of VEGF in retinal Mu¨ller cells
[33] and proximal tubular cells [34]. Moreover it has been
observed that VEGF protein level increased in DRG neurons and
sciatic nerve axons from chronic STZ diabetic rats [35]. These
findings strengthened the hypothesis of a key role of VEGF also in
the pathogenesis of DN, like already demonstrated in diabetic
retinopathy and nephropathy [36,37].
We demonstrated that hyperglycaemia inversely modified FLT-
1 protein level in DRG neuron monocultures (where it increased)
and SC (where it decreased). FLT-1 is a cell-surface receptor for
VEGF and may function as negative regulator limiting the amount
of free VEGF and preventing its binding to VEGF receptor-2
(KDR), the best characterized receptor and known to mediate
most VEGF cellular responses [38]. We also found that sFLT-1
was decreased. This soluble receptor lacks one transmembrane
domain and may function as a decoy for VEGF. We speculated
that in hyperglycaemia VEGF overruled sFLT-1 whose scavenger
activity could not limit VEGF increase and its toxic effects.
We showed that bevacizumab, a recombinant humanized
monoclonal IgG1 antibody that binds VEGF and inhibits its
Figure 7. Bevacizumab prevented and restored peripheral nerve functions in diabetic rats. Control and STZ-diabetic rats were treated
with bevacizumab according to the prevention (A, B, C) or therapeutic (D, E, F) schedule. (A) Bevacizumab prevented in a dose-dependent fashion
thermal hypoalgesia, (B) mechanical threshold decrease and (C) nerve conduction velocity decrease in diabetic rats. In the therapeutic schedule,
bevacizumab restored (D) thermal hypoalgesia (E) mechanical threshold and (F) nerve conduction velocity decrease in diabetic rats. Data are
expressed as mean6SEM (n= 8 animals per group) *p,0.05 vs controls; **p,0.01 vs controls; ****p,0.001 vs controls;#*p,0.05 vs STZ;##p,0.01
vs STZ.
doi:10.1371/journal.pone.0108403.g007
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biologic activity preventing the interaction to its receptors, was
protective both in vitro and in vivo models of DN. Indeed, it
reduced the level of free VEGF in the medium of DRG co-cultures
exposed to hyperglycaemia and protected from the impairment of
neurite outgrowth in a dose-dependent fashion. This was
associated with the normalization of FLT-1 signaling between
neurons and SC. Exposition of hyperglycaemia-conditioned DRG
neuron monocultures to bevacizumab normalized FLT-1 mRNA
with no change at the protein level. Conversely, exposition of
hyperglycaemia-conditioned SC monocultures to bevacizumab
increased FLT1 protein and reduced FLT-1 mRNA.
Finally, we demonstrated that bevacizumab both protected and
reversed neuropathy in STZ rats, confirming the neuroprotective
effects of our in vitro studies. Indeed, preventive and therapeutic
protocols of bevacizumab administration counteracted in a dose-
dependent fashion the pathological changes in thermal and
mechanical thresholds, and in NCV which are hallmarks of
diabetic neuropathy. Modulation of the VEGF/FLT1 signalling
axis in vivo have to be further investigate in order to attribute
efficacy of bevacizumab to a specific mechanism. Few and
contradictory data are available on the role of VEGF in DN.
Some works showed neuroprotective effects of VEGF on sensory
and motor neurons [39–41], whereas others provided convincing
evidence of direct toxic effects on nerves [42] which are reversed
by bevacizumab [43]. A recent study reported significantly higher
levels of serum VEGF in diabetic patients with neuropathy
compared to those without neuropathy [44]. In the STZ model of
experimental diabetes it has been reported that VEGF expression
increased in DRG and sciatic nerves and that insulin and/or nerve
growth factor administration could prevent it [35].
Conclusions
We provided evidence of the pathogenetic role of VEGF in
experimental DN. Our findings are in keeping with previous
studies showing the direct involvement of VEGF in other long-
term complications of diabetes, as demonstrated by its detrimental
effects on retina [36] and kidney [45], the elevated serum levels
[37,46] and, most importantly, the beneficial effects of anti-VEGF
treatment in patients with diabetic retinopathy and nephropathy
[47–50]. We suggest that appropriate clinical trials should be
designed to test the efficacy of anti-VEGF drugs also in DN
patients.
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